Is Tarsus Pharmaceuticals Inc (TARS) Stock About to Get Hot Tuesday?

Overall market sentiment has been high on Tarsus Pharmaceuticals Inc (TARS) stock lately. TARS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Tarsus Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TARS!

See Full TARS Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With TARS Stock Today?

Tarsus Pharmaceuticals Inc (TARS) stock is trading at $16.04 as of 11:53 AM on Tuesday, Nov 7, a rise of $0.03, or 0.19% from the previous closing price of $16.01. Volume today is less active than usual. So far 122,248 shares have traded compared to average volume of 485,714 shares. The stock has traded between $15.75 and $16.45 so far today.

More About Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Click Here to get the full Stock Report for Tarsus Pharmaceuticals Inc stock.